Importantly, BIC could block both EMT and FMT processes induced by either direct addition of TGF-β1 or the supernatant containing TGF-β1 in a dose-dependent manner, suggesting that TGF-β1 could serve as a therapeutic target of BIC against silicosis. This evidence concerns the gene TGFB1 and silicosis.